SCHEMBL2602822

SCHEMBL2602822

C[C@H](COP(=O)(O)OCC[N+](C)(C)C)OCCCCC(=O)O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FABP3 P05413 1/20 0.48
▸ RECQL P46063 1/20 0.44
▸ P2RY10 O00398 4/20 0.38
▸ GPR34 Q9UPC5 2/20 0.38
▸ ALDH1A1 P00352 1/20 0.37
▸ PLA2G10 O15496 1/20 0.36
▸ MAPK1 P28482 4/20 0.36
▸ MEN1 O00255 2/20 0.36
▸ GMNN O75496 2/20 0.36
▸ LMNA P02545 2/20 0.36
▸ MAPT P10636 2/20 0.36
▸ BLM P54132 2/20 0.36
▸ KMT2A Q03164 2/20 0.36
▸ NPSR1 Q6W5P4 2/20 0.36
▸ TP53 P04637 2/20 0.36
▸ CYP3A4 P08684 2/20 0.36
▸ CYP2D6 P10635 2/20 0.36
▸ CYP2C9 P11712 2/20 0.36
▸ ALOX15 P16050 2/20 0.36
▸ NFKB1 P19838 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20436157 0.86 RECQL (0.59) RECQLPLA2G10MAPK1MEN1GMNN
SCHEMBL2605938 0.85 FABP3 (0.52) FABP3RECQLALDH1A1MAPK1MEN1
SCHEMBL15336411 0.85 FABP3 (0.52) FABP3RECQLP2RY10GPR34MAPK1
SCHEMBL14080851 0.83 FABP3 (0.50) FABP3RECQLP2RY10GPR34ALDH1A1
SCHEMBL27966574 0.83 RECQL (0.59) FABP3RECQLALDH1A1MAPK1MEN1
SCHEMBL12581828 0.82 ALDH1A1 (0.37) P2RY10GPR34ALDH1A1
SCHEMBL2602820 0.81 FABP3 (0.42) FABP3ALDH1A1MAPK1MEN1GMNN
SCHEMBL16982402 0.81 FABP3 (0.50) FABP3RECQLP2RY10GPR34MAPK1
SCHEMBL2605941 0.81 FABP3 (0.40) FABP3ALDH1A1MAPK1MEN1GMNN
SCHEMBL13352018 0.81 ALDH1A1 (0.40) P2RY10GPR34ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8563534-B2 Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis VASCULAR BIOGENICS LTD. (IL) 2013-10-22 — — US disclosed
EP-1626728-B1 OXIDIZED LIPIDS AND USES THEREOF IN THE TREATMENT OF INFLAMMATORY DISEASES AND DISORDERS VASCULAR BIOGENICS LTD (IL) 2013-07-10 — — EP disclosed
US-20120329757-A1 Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis VASCULAR BIOGENICS LTD. (IL) 2012-12-27 — — US disclosed
US-8158611-B2 Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis VASCULAR BIOGENICS LTD. (IL) 2012-04-17 — — US disclosed
US-20110097350-A1 METHODS EMPLOYING AND COMPOSITIONS CONTAINING DEFINED OXIDIZED PHOSPHOLIPIDS FOR PREVENTION AND TREATMENT OF ATHEROSCLEROSIS VASCULAR BIOGENICS LTD. (IL) 2011-04-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120329757-A1 Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis PHOSPHO1, GPX4, SGMS1 FABP3 251/4885RECQL 1895/4885P2RY10 3364/4885
US-20110097350-A1 METHODS EMPLOYING AND COMPOSITIONS CONTAINING DEFINED OXIDIZED PHOSPHOLIPIDS FOR PREVENTION AND TREATMENT OF ATHEROSCLEROSIS PHOSPHO1, GPX4, SGMS1 FABP3 251/4885RECQL 1895/4885P2RY10 3364/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback